PROVENGE Targets and Attacks

PROVENGE targets and attacks prostate cancer cells. Start early to activate the power of the immune system.

Learn More

PROVENGEProlongs Survival

PROVENGE, a first-line advanced prostate cancer treatment, delivers a statistically significant survival advantage by extending median overall survival beyond 2 years.1,2

Learn More

Short Therapy Duration and Sustained Immune Response*

PROVENGE has a short duration of therapy (approximately 1 month) and has demonstrated a sustained immune response, which was seen out to 26 weeks in the pivotal study (the last time point measured).1

Learn More

For Newly MetastaticCRPC Patients

PROVENGE is recommended by the NCCN as first-line treatment for asymptomatic or minimally symptomatic metastatic CRPC.3 Consider PROVENGE for patients:

  • With metastatic CRPC
  • Who are asymptomatic or minimally symptomatic
  • Who do not require narcotic analgesics for cancer-related pain

Learn More

*A sustained immune response was seen out to 26 weeks in the pivotal study (the last time point measured).1 Castrate-resistant prostate cancer
National Comprehensive Cancer Network

Prescribe PROVENGE

Become a PROVENGETreatment Center

Help your patients sustain* their fight against advanced prostate cancer by providing PROVENGE.

Comprehensive Support

Whether you want to become a treatment center or need help navigating the reimbursement and insurance benefits certification process, we’ve got you covered with a personal coordinator who can guide you throughout the prostate cancer treatment process.

Learn More


Watch a video to learn how to infuse PROVENGE safely and appropriately.

Watch Video


The PROVENGE Practice Pathway Resource Guide is an interactive reference source designed to help integrate PROVENGE therapy into your practice.

View now

This site is intended for US Health Care Professionals only.

PROVENGE® (sipuleucel-T) is approved by the FDA as an autologous cellular immunotherapy for the treatment of asymptomatic or minimally symptomatic metastatic castrate resistant (hormone refractory) prostate cancer.

PROVENGE is intended solely for autologous use and is not routinely tested for transmissible infectious diseases.

In controlled clinical trials, serious adverse events reported in the PROVENGE group included acute infusion reactions (occurring within 1 day of infusion) and cerebrovascular events. Severe (Grade 3) acute infusion reactions were reported in 3.5% of patients in the PROVENGE group. Reactions included chills, fever, fatigue, asthenia, dyspnea, hypoxia, bronchospasm, dizziness, headache, hypertension, muscle ache, nausea, and vomiting. No Grade 4 or 5 acute infusion reactions were reported in patients in the PROVENGE group.

The most common adverse events (incidence ≥ 15%) reported in the PROVENGE group were chills, fatigue, fever, back pain, nausea, joint ache, and headache.

Please see the Full Prescribing Information.

  1. PROVENGE [package insert]. Dendreon Corporation; June 2011.
  2. Kantoff PW, Higano CS, Shore ND, et al; for the IMPACT Study Investigators. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363:411-422.
  3. NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer. V.2.2013. National Comprehensive Cancer Network Web site. Accessed May 21, 2013.